Saturday 17 October 2026
Export PMN’s income statement to Excel — free account
Promis Neurosciences
In the quarter to June 2026, EPS grew 82.3% and free cash flow fell 169.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.15
0.55
−6.32%
Follow PMN
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 60.00 | 165.00 | 210.00 | 180.00 | 75.00 | 90.00 | 105.00 | 23.75 | 21.75 | 6.27 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 240.00 | 1,050.00 | 885.00 | 510.00 | 345.00 | 345.00 | 245.00 | 223.75 | 77.50 | 39.75 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 7 | 7 | 8 | 11 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | ||||
| Gross margin, % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (3) | (5) | (8) | (6) | (4) | (10) | (18) | (13) | 3 | (40) | |||||
| EBT margin, % | (130,460.00) | (61,102.63) | (1,960,975.00) | (619,311.11) | (325,153.85) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (3) | (5) | (8) | (6) | (4) | (10) | (18) | (13) | 3 | (40) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.02 | 0.06 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (22.99) | (29.94) | (44.91) | (29.94) | (22.16) | (42.30) | (60.25) | (26.75) | 2.75 | (22.61) | |||||
| Cash flow | (16.93) | (31.97) | (41.73) | (26.45) | (17.04) | (40.21) | (56.76) | (22.05) | (26.21) | (16.00) | |||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | (0.43) | 0.40 | (0.01) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (16.93) | (31.97) | (41.73) | (26.45) | (17.46) | (39.81) | (56.77) | (22.05) | (26.21) | (16.00) | |||||
| Book value | 0.46 | 8.60 | 5.58 | 1.73 | (3.97) | 24.46 | (4.49) | 7.63 | 15.90 | (0.72) | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | ||||
| P/S | 0.00 | 0.00 | 159,800.00 | 30,756.82 | 10,407.27 | — | — | — | — | — | |||||
| P/B | 0.00 | 27.90 | 53.74 | 112.78 | 0.00 | — | — | — | — | — | |||||
| EV/Sales | 0.00 | 0.00 | 153,547.67 | 29,589.73 | 10,043.86 | — | — | — | — | — | |||||
| EV/FCF | 0.00 | (7.20) | (6.91) | (7.09) | (6.80) | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (2) | (4) | (7) | (5) | (3) | (9) | (17) | (11) | (27) | (28) | ||||
| Capex | — | — | — | — | 0 | 0 | 0 | — | — | — | |||||
| Free cash flow | (2) | (4) | (7) | (5) | (3) | (9) | (17) | (11) | (27) | (28) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 0 | 1 | 1 | 0 | (1) | 17 | 0 | 4 | 17 | (1) | ||||
| Total debt | — | — | — | — | — | 4 | — | — | — | — | |||||
| Net debt | (1) | (1) | (2) | (1) | (1) | (13) | (6) | (13) | (13) | (6) | |||||
| Shareholders’ equity | 0 | 1 | 1 | 0 | (1) | 6 | (1) | 4 | 16 | (1) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | 0.00 | (386.10) | (395.87) | (289.47) | (325.59) | (104.26) | (146.42) | (128.63) | 17.08 | (282.76) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (332.40) | 0.00 | |||||
| ROE | 0.00 | (751.91) | (756.07) | (935.12) | 1,844.24 | (399.46) | (837.71) | (1,098.52) | 27.46 | (521.61) | |||||
Negative figures in brackets.
Fiscal years to Dec 2020 · latest quarter Dec 2020
Charts ten years each
Promis Neurosciences vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NMRA Neumora Therapeutics, Inc. | $80.2M | — (loss-making) | — | — | n/m | +24.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CLLS Cellectis S.A. | $79.9M | — (loss-making) | — | −62.05% (below 0%: shrinking) | n/m | −36.95% (below 0%: shrinking) | 100.00% | (340.69%) | Compare |
| PMN Promis Neurosciences | $78.0M | — (loss-making) | — | 0.00% | n/m | −169.46% (below 0%: shrinking) | 0.00% | 0.00% | |
| PTHS Pelthos Therapeutics Inc. | $77.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| TELO Telomir Pharmaceuticals, Inc. | $77.3M | — (loss-making) | — | — | n/m | −45.34% (below 0%: shrinking) | — | 0.00% | Compare |
| NTRB Nutriband Inc. | $76.2M | — (loss-making) | 4.6× | −29.72% (below 0%: shrinking) | n/m | +55.46% (above 0%: growing) | 41.58% | (203.57%) | Compare |
| CRDF Cardiff Oncology, Inc. | $75.5M | — (loss-making) | — (loss-making) | −14.05% (below 0%: shrinking) | n/m | −41.36% (below 0%: shrinking) | 100.00% | (9,245.19%) | Compare |
| ACRV Acrivon Therapeutics, Inc. | $75.4M | — (loss-making) | — | — | n/m | +12.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| OKYO OKYO Pharma Limited Sponsored ADR | $75.1M | — (loss-making) | — | — | n/m | +37.39% (above 0%: growing) | 0.00% | — | Compare |
| Median of peers | $76.8M | — | — | −29.72% | — | −12.18% | 41.58% | (111.02%) |
Promis Neurosciences (PMN) key facts
- Promis Neurosciences (PMN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, PMN traded at $8.15, a market capitalization of $78.0 million.
- Return on equity was −521.6% and debt-to-equity 0.00.
Promis Neurosciences (PMN) Latest News
No news at this impact. Lower the threshold for more.